endostar + chemotherapy

Endostar + chemotherapy refers to the combination of recombinant human endostatin (Endostar), an antiangiogenic agent, with standard chemotherapy regimens (such as platinum-based doublet chemotherapy, e.g. cisplatin, paclitaxel, vinorelbine) for cancer treatment. Endostar is a recombinant derivative of endostatin, approved in China for the treatment of non-small cell lung cancer (NSCLC) and studied in other cancers. Endostar inhibits tumor angiogenesis primarily by blocking the vascular endothelial growth factor (VEGF) pathway, specifically by inhibiting VEGF-induced tyrosine phosphorylation and expression of VEGF receptor 2 (VEGFR2/KDR/Flk-1), and modulating related signaling cascades like ERK, p38 MAPK, and AKT. The combination with chemotherapy is intended to enhance antitumor efficacy: Endostar’s normalization of tumor vasculature can increase tumor perfusion and drug delivery, and its hypoxia-modulating effects may enhance radiotherapy or chemotherapeutic sensitivity. Clinical studies in NSCLC and cervical cancer have demonstrated that Endostar plus chemotherapy can improve objective response rates, progression-free survival, and (in some subgroups) overall survival, without substantially increasing adverse events relative to chemotherapy alone.

Other names

recombinant human endostatin + chemotherapy